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2. Molecular structure of fibronectin 
 
 
Figure SI_1: The modular structure of the extracellular matrix protein 
fibronectin. Even when the essential RGD recognition motif in 
domain III-10 (grey circle) is mutated to RGE, the protein still 
binds to αvβ3 and α5β1 integrin receptors. Previous studies 
revealed that this unexpected observation can be attributed to 
a rearrangement of the NGR amino acid sequence in domain 
I-5 (grey rectangle) into isoDGR. The NGR motif is also 
located at three further positions. The deamidation of 
asparagine, usually regarded as a process of protein 
degradation, results in an activation of fibronectin. 
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3. Synthesis of peptides  
 
3.1 Materials and methods 
Tritylchloride polystyrene (TCP) resin (0.94 mmol/g) was purchased from 
PepChem (Tübingen Germany). Coupling reagents and amino acid 
derivatives were purchased from Merck Biosciences (Läufelfingen, 
Switzerland), Perseptive Biosystems GmbH (Hambourg, Germany) and 
Neosystem (Strasbourg, France). All other reagents and solvents were 
purchased from Merck (Darmstadt, Germany), Aldrich (Steinheim, Germany) 
and Fluka (Neu-Ulm, Germany) and were used as received. Standard syringe 
techniques were applied for transferring dry solvents. Reactions on solid 
support were performed in filter columns (2 mL) from Abimed.  
Analytical and preparative HPLC was performed on A) Amersham Pharmacia 
Biotech: Äkta Basic 10F; Pump system P-900; Detector UV-900; Driver 
software Unicorn, vers. 3.00; Column material: ODS-A C18 (120 Å, 5 µm, 250 
mm x 4.6 mm); B) Amersham Pharmacia Biotech: Äkta Basic 100F; Pump 
system P-900; Detector UV-900, Driver software Unicorn vers. 3.00; Column 
material ODS-A C18 (120 Å, 10 µm, 250 mm x 20 mm). ESI mass spectra 
were recorded on a Finnigan LCQ combined with an HPLC-system Hewlett 
Packard HP1100 (Column material: Omnicrom YMC ODS-A C18 (120 Å, 3 µm, 
125 mm x 2 mm). NMR spectra were recorded on Bruker AC250 and 
DMX500 using DMSO-d6 as solvent and internal standard. Assignment was 
performed using different 2D-experiments such as TOCSY, HMQC-COSY. All 
yields are not optimized.  
 
3.2 General procedure 
Loading of TCP resin 
Peptide synthesis was carried out using TCP resin (0.94 mmol/g) following 
standard Fmoc strategy.[1] Fmoc-Arg(Pbf)-OH (1.2 eq) was attached to the 
TCP resin with DIEA (2.5 eq) in anhydrous DCM (2 mL) at room temperature 
for 1 h. After filtration, the remaining trityl chloride groups were capped by a 
solution of DCM, MeOH, DIEA (17 : 2 : 1; v : v : v) for 15 min. The resin was 
filtered and washed thoroughly with DCM (2×), DMF (3×) and MeOH (5×). The 
loading capacity was determined by weight after drying the resin under 
vacuum, and ranged from 0.40 to 0.65 mmol/g. 
 
Solid phase Fmoc deprotection 
The resin-bound Fmoc peptide was treated with 20% piperidine in NMP (v/v) 
for 5 min and a second time for 15 min. The resin was washed with NMP (5×) 
 
Solid phase peptide coupling with HOBt / TBTU 
A solution of Fmoc-Xaa-OH (3 eq), TBTU (3 eq), HOBt (3 eq), DIEA (6 eq) in 
NMP was added to the resin-bound free amine peptide and shaken for 1 h at 
room temperature. The resin was washed with NMP (5×). 
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Cleavage of side-chain-protected peptides from TCP resin 
The resin-bound peptide was treated three times with a 20% solution of HFIP 
(hexafluoroisopropanol) in DCM (v/v) for 30 min. The collected solutions were 
concentrated in vacuo. 
 
Cleavage and full deprotection of peptides from TCP resin 
The resin-bound peptide was treated three times with a mixture of TFA, water, 
triisopropylsilane (95% : 2.5% : 2.5%, v : v : v) for 1 h. The deprotected 
peptide precipitated was spun down in a centrifuge after adding diethyl ether, 
washed twice with ether and dried under vacuum. The deprotection was 
followed by ESI-MS.  
 
Backbone cyclization of peptides 
The head-to-tail cyclization was performed with diphenylphosphorylacid azide 
(DPPA), applying the solid base method using NaHCO3 in N,N-
dimethylformamide (DMF). After the completion of cyclization, which was 
monitored by ESI mass spectroscopy, DMF was evaporated and the peptide 
was dissolved in ethyl acetate, which precipitated the cyclization reagents and 
left the crude product dissolved in ethyl acetate and washed three times with 
a solution of NaHCO3 and once with brine.  
 
Full deprotection of cyclic peptides 
The cyclic peptide was treated with a mixture of TFA, water, triisopropylsilane 
(95% : 2.5% : 2.5%, v : v : v) for 1 h. The deprotected peptide precipitated 
was spun down in a centrifuge after adding diethyl ether, washed twice with 
ether and dried under vacuum. The deprotection was followed by ESI-MS. 
The pure compound was obtained by reversed phase high-performance liquid 
chromatography (RP-HPLC) purification. The peptides were characterized by 
ESI mass spectroscopy. 
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4. Characterization of peptides  
 
Compound 
No. 
Sequence 
ESI-MS 
(M+H)+ 
HPLC-
Gradient 
Retention 
time [min] 
I f-isoDGR-V 575 10-100% 11.10 
II F-isodGR-V 575 10-100% 11.26 
III FisoDGR-V 575 10-100% 11.27 
IV F-isoDGr-V 575 10-100% 11.22 
V F-isoDGR-v 575 10-100% 11.55 
VI G-isodGR-G 443 0-100% 7.10 
VII G-isoDGr-G 443 0-100% 7.17 
VIII F-isodGR-G 533 10-100% 8.67 
IX F-isoDGr-G 533 10-100% 8.74 
X Hphe-isodGR-G 547 10-100% 10.15 
XI Hphe-isoDGr-G 547 10-100% 10.29 
XII Phg-isodGR-G 519 10-100% 7.18 
XIII Phg-isoDGr-G 519 10-100% 7.06 
1 G-isoDGR-G 443 0-100% 7.01 
2 F-isoDGR-G 533 10-100% 8.59 
3 f-isoDGR-G 533 10-100% 8.02 
4 G-isoDGR-F 533 10-100% 8.20 
5 G-isodGR-f 533 10-100% 8.02 
6 Hphe-isoDGR-G 547 10-100% 9.83 
7 hphe-isoDGR-G 547 10-100% 9.54 
8 G-isoDGR-Hphe 547 10-100% 9.38 
9 G-isoDGR-hphe 547 10-100% 9.53 
10 Phg-isoDGR-G 519 10-100% 6.83 
11 phg-isoDGR-G 519 10-100% 7.18 
12 G-isoDGR-Phg 519 10-100% 7.12 
13 G-isoDGr-phg 519 10-100% 7.00 
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5. Integrin activity data  
 
Compound 
No. 
Sequence IC50 α5β1 [nM] IC50 αvβ3 [nM]
I f-isoDGR-V 846 50 
II F-isodGR-V 2004 100 
III FisoDGR-V 31892 >1000 
IV F-isoDGr-V >40000 >1000 
V F-isoDGR-v 1860 50 
VI G-isodGR-G 7638 >1000 
VII G-isoDGr-G 8035 >1000 
VIII F-isodGR-G >1700 >1000 
IX F-isoDGr-G 1279 >1000 
X Hphe-isodGR-G >20000 >1000 
XI Hphe-isoDGr-G 812 >1000 
XII Phg-isodGR-G 7031 >1000 
XIII Phg-isoDGr-G 711 >1000 
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6. Solid phase binding assay  
 
The inhibiting activity and integrin selectivity of the integrin inhibitors were 
determined in a solid phase binding assay using soluble integrins and coated 
extracellular matrix proteins. Binding of integrins was than detected by 
specific antibodies in an enzyme-linked immunosorbent assay. Fibronectin 
and vitronectin were purchased from Sigma (St. Louis, MO), the integrin α5β1 
was purchased from R&D Systems (Minneapolis, MN) and αVβ3 from 
Chemicon (Chemicon Europe, Germany). The integrin antibodies were 
purchased from Pharmingen, BD Bioscience Europe (mouse anti-human 
CD51/CD61, and mouse anti-human CD49e) and Sigma (anti-mouse-HRP 
conjugate). The detection of HRP was performed using HRP substrate 
solution 3.3.5.5’-tetramethylethylenediamine (TMB, Seramun, Germany) and 
2 M H2SO4 for stopping the reaction. The developed color was measured at 
450 nm with a POLARstar Galaxy plate reader (BMG Labtechnologies). Every 
concentration was analyzed by duplicate and the resulting inhibition curves 
were analyzed using OriginPro 7.5G software, the turning point describes the 
IC50 value. 
 
α5β1: BRAND flat-bottom 96-well ELISA plates were coated over night at 4°C 
with fibronectin (0.50 µg/mL) in 15 mM Na2CO3, 35 mM NaHCO3, pH 9.6. 
Plates were subsequently washed three times with PBST buffer (137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM  KH2PO4, 0.01% Tween 20, pH 
7.4) and blocked for one hour at room temperature with 150 µL/well of TSB-
buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM 
MnCl2, pH 7.5, 1% BSA). Soluble integrin α5β1 (1.0 µg/mL) and a serial 
dilution of integrin inhibitor in TSB were incubated in the coated wells for 1 h 
at room temperature. The plate was then washed three times with PBST 
buffer and 100 µL/well of primary antibody (CD49e) were incubated at 1.0 
µg/mL in TSB (1:500 dilution) for 1 h at room temperature. After washing tree 
times with PBST, 100 µL/well of the secondary anti-body (anti-mouse-HRP 
conjugate) were applied at 2.0 µg/mL in TSB (1:385 dilution) for 1 h at room 
temperature. After this treatment the plate was washed three times and the 
binding visualized as described above. 
 
For the αvβ3 assay, plates were coated with vitronectin (1.0 µg/mL) and 
blocked as described for α5β1. Soluble αVβ3 (1.0 µg/mL) was incubated with 
a serial dilution of integrin inhibitor for one hour at room temperature. Primary 
(CD51/CD61, 2.0 µg/mL, 1:250 dilution) and secondary antibody (anti-mouse-
HRP conjugate, 1.0 µg/mL, 1:770 dilution) were applied each for 1 h at room 
temperature and the binding visualized as described above.  
 
The peptides I to XIII were tested by Jerini AG with a slightly different 
method.[2] 
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7. NMR Spectroscopy of the peptides 11 and 13 
 
Each 5 mg of the peptides 11 and 13 were dissolved in 500 µl d6-DMSO; the 
solvent was also used for the lock signal. All spectra were recorded on a 
Bruker DMX500 spectrometer equipped with a 5 mm TXI RT probe head and 
referenced to the B0 magnetic field. Purity and conformational equilibria of the 
compounds were checked via 1H-1D spectra. For both peptides, only one 
signal set was observed in the NMR spectra. Atom and atom group 
assignment was done via E.COSY[3] and TOCSY[4] spectra; sequential 
assignment was accomplished by through-bond connectivities from 
heteronuclear multiple bond correlation (1H,13C-HMBC)[5] spectra. 
Connectivities were proved by interresidual scalar couplings, e.g between 
carbonyl carbons and adjacent amide protons. ROESY[6] spectra were 
recorded to extract information about pair-wise proton-proton distances. 
Homonuclear J-couplings were extracted from E.COSY spectra. For TOCSY, 
ROESY, and E.COSY spectra, 16 k data points were recorded in the direct 
dimensions and 512 data points in the indirect dimensions (2 k data points for 
E.COSY). QSINE window functions and zero filling to twice the number of 
recorded points were used for processing. HMBC spectra were recorded with 
4 k data points in the F2 and 256 data points in the F1 dimensions; for 
processing, SINE and QSINE functions as well as zero filling to twice the 
number of recorded points were used. TOCSY spectra were recorded with a 
mixing time of 80 ms, ROESY spectra with a mixing time of 150 ms, thus 
avoiding unwanted effects caused by spin diffusion. The temperature of all 
measurements was 300 K. The software tools TOPSPIN and SPARKY were 
utilized to process spectra, to assign resonances, and for ROE peak volume 
integration. Proton distances were calculated according to the isolated two-
spin approximation.[7] No ROE offset correction was performed since biasing 
offset effects at the field strength used in this study are rather small. The 
integrated volumes of ROE cross peaks were converted to proton–proton 
distances by the help of calibration to distances between methylene protons 
(1.78 Å). Upper and lower distance restraints were obtained by adding and 
subtracting 10 % to / from the calculated experimental values, thus accounting 
for experimental errors and simulation uncertainties. 
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8. Structure calculation of the peptides 11 and 13 
 
Calculation of the most representative conformations of 11 and 13 was done 
by distance geometry (DG) and molecular dynamics (MD) simulations. Metric 
matrix DG calculations were carried out with a distance geometry algorithm 
utilizing random metrization.[8] Experimental distance restraints which are 
more restrictive than the geometric distance bounds (holonomic restraints) 
were used to create the final distance matrix. All structure templates were first 
embedded in four dimensions and then partially minimized using conjugate 
gradient minimization followed by distance-driven dynamics (DDD) wherein 
only distance constraints were used.[9] The DDD simulation was carried out at 
1000 K for 50 ps with a gradual reduction in temperature over the next 30 ps. 
The DDD procedure utilized holonomic and experimental distance constraints 
plus a chiral penalty function for the generation of violation energies and 
forces. A distance matrix was calculated from each structure, and the EMBED 
algorithm was used to compute Cartesian coordinates in three dimensions.[10] 
50 structures were calculated for each peptide, and > 95 % of the structure 
bundles of both peptides did not show any significant violations (> 0.12 Å). 
MD calculations were carried out with the program Gromacs version 3.3.3.[11] 
The Gromos G53a6 force field as implemented in Gromacs was used for 
parametrization of the peptide and DMSO solvent molecules.[12] The most 
representative DG structures of the peptides were first energy minimized by 
the conjugate-gradient[13] algorithm and then placed in truncated octahedral 
simulation boxes with the box walls being at least 1.6 nm away from the 
solutes. The boxes were each filled with more than 600 DMSO solvent 
molecules and subsequently energy minimized with the steepest descent 
algorithm whereas all atoms of the solutes were positionally restrained to their 
original positions (F = 2.5 E+005 kJ / mol). Afterwards, both boxes were 
heated up to 360 K (higher simulation temperatures compared to 
experimental ones in order to overcome higher energy barriers) in six steps 
and the position restraints were stepwise lowered until the positional forces 
reach 0 kJ / mol (each equilibrium run was simulated for 50 ps). The average 
temperature was maintained via the Berendsen[14] algorithm  as implemented 
in Gromacs 3.3.3. Then, Berendsen pressure coupling[14] was turned on for 
500 ps. Production runs were 250 ns long. Intermolecular interactions were 
treated with a twin-range cutoff of 0.8 nm and 1.4 nm. The pair-lists were 
updated each after five integration steps. Behind the long-range cutoff, a 
reaction-field (epsilon_rf = 38) was used to calculate long-range Coulombic 
interactions. A leap-frog algorithm was utilized to integrate Newton’s equation 
of motion with a integration time step of 2 fs.[15] All bonds were constrained 
applying the SHAKE[16] algorithm. In addition, periodic boundary conditions 
were utilized and the center-of-mass motion was removed every 500 
integration steps. The two peptides were simulated both as fully neutral (ARG 
and isoASP uncharged) and as zwitter ionic (ARG and isoASP charged) 
species in separated runs. Evaluation of ROE based distance restraints and 
of J-couplings was performed via tools as implemented in the Gromos2005 
MD software package.[17] Pseudo-atom and multiplicity corrections for 
distance restraints were applied as described by Koning et al.[18] The peptides 
were presented in Fig. 2 as vacuum energy minimized conformations. 
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9. NMR & MD data for peptide 11: c(-DPhg-Iasp-Gly-Arg-Gly-) 
 
a) Assignment (given in ppm)  
1DPHG 2IASP 3GLY 4ARG 5GLY 
NH --- 8.60 NH --- 7.84 NH --- 8.42 NH --- 8.42 NH --- 8.03 
HA --- 5.50 HA --- 4.47 HA1 pro-R 3.61 HA --- 4.06 HA1 pro-R 3.70 
HD* --- 7.46 HB1 pro-R 2.57 HA2 pro-S 3.89 HB1 pro-R 1.61 HA2 pro-S 3.88 
HE* --- 7.35 HB2 pro-S 2.82  HB2 pro-S 1.79 
HZ --- 7.33  HG* --- 1.51 
HD* --- 3.12 
 
 
HE --- 7.66  
 
b) ROE distance restraints 
Assignment Experimental (Å) Zwitter (Å) Uncharged (Å) Combined (Å) 
No AS-1 At-1 AS-2 At-2 Upper Lower Calc Viol Calc Viol Calc Viol 
01 1DPHG NH 1DPHG HA 3.20 2.62 2.68  2.72  2.70  
02 2IASP NH 1DPHG HA 3.54 2.90 3.13  2.87 - 0.03 3.00  
03 2IASP NH 2IASP HA 2.84 2.32 2.69  2.73  2.71  
04 3GLY NH 2IASP HA 4.21 3.45 4.02  3.81  3.92  
05 2IASP NH 2IASP HB1 3.75 3.07 3.35  3.18  3.27  
06 3GLY NH 2IASP HB1 3.00 2.46 2.60  3.35 + 0.35 2.85  
07 2IASP NH 2IASP HB2 3.56 2.92 2.63 - 0.29 3.78 + 0.22 2.97  
08 3GLY NH 2IASP HB2 2.64 2.16 2.39  2.28  2.33  
09 1DPHG NH 2IASP NH 2.77 2.27 2.49  2.64  2.55  
10 4ARG NH 4ARG HA 3.14 2.56 2.76  2.13 - 0.43 2.39 - 0.17 
11 5GLY NH 4ARG HA 2.76 2.26 2.82 + 0.06 2.19 - 0.07 2.46  
12 4ARG HA 4ARG HB2 2.87 2.35 2.57  2.49  2.54  
13 4ARG HE 4ARG HB2 3.71 3.03 3.48  3.78 + 0.07 3.60  
14 4ARG NH 4ARG HB2 3.37 2.75 3.11  3.66 + 0.29 3.32  
15 1DPHG NH 5GLY HA2 3.01 2.47 2.34 - 0.13 2.41 - 0.06 2.37 - 0.10 
16 1DPHG NH 5GLY HA1 3.35 2.75 3.18  3.29  3.23  
17 1DPHG NH 5GLY NH 3.09 2.53 3.17 + 0.08 2.83  3.00  
18 4ARG NH 5GLY NH 3.16 2.58 2.60  3.07  2.78  
19 2IASP HA 2IASP HB1 2.68 2.20 2.40  2.34  2.37  
20 3GLY NH 2IASP NH 3.69 3.01 3.90 + 0.21 3.82 + 0.13 3.86 + 0.17 
21 5GLY NH 2IASP NH 3.95 3.23 3.99 + 0.04 2.86 - 0.37 3.29  
22 5GLY NH 5GLY HA1 2.93 2.39 2.65  2.73  2.69  
23 5GLY NH 5GLY HA2 2.93 2.39 2.57  2.50  2.54  
24 1DPHG NH 4ARG NH 5.39 4.41 5.16  5.18  5.17  
25 3GLY NH 3GLY HA1 2.73 2.23 2.29  2.28  2.28  
26 3GLY NH 3GLY HA2 2.52 2.06 2.66 + 0.14 2.73 + 0.21 2.69 + 0.17 
27 2IASP HA 2IASP HB2 2.95 2.41 2.70  2.34 - 0.07 2.51  
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Assignment Experimental (Å) Zwitter (Å) Uncharged (Å) Combined (Å) 
28 1DPHG HE* 1DPHG HA 5.74 2.98 4.71  4.71  4.71  
29 1DPHG NH 1DPHG HE* 6.22 3.38 4.96  4.80  4.88  
30 2IASP NH 1DPHG HE* 6.80 3.84 5.37  6.03  5.63  
31 1DPHG NH 1DPHG HD* 5.30 2.62 2.70  2.61 - 0.01 2.66  
32 2IASP NH 1DPHG HD* 5.95 3.15 3.19  3.57  3.35  
33 4ARG HD* 4ARG HB2 4.00 2.54 2.83  2.93  2.87  
34 4ARG HA 4ARG HD* 4.20 2.70 3.64  3.11  3.35  
 
c) J-Couplings 
Assignment Zwitter (Hz) Uncharged (Hz) Combined (Hz) 
AS At-1 At-2 Chiral Exp Calc Viol Exp Calc Viol Exp Calc Viol 
1DPHG NH HA --- 8.5 8.0 0.5 8.5 8.0 0.5 8.5 8.0 0.5 
2IASP NH HA --- 7.9 7.5 0.4 7.9 6.9 1.0 7.9 7.3 0.6 
2IASP HA HB1 pro-R 4.1 3.3 0.8 4.1 3.2 0.9 4.1 3.3 0.8 
2IASP HA HB2 pro-S 7.0 9.4 2.4 7.0 3.8 3.2 7.0 6.9 0.1 
3GLY NH HA1 pro-R 5.4 5.3 0.1 5.4 6.0 0.6 5.4 5.7 0.3 
3GLY NH HA2 pro-S 6.6 5.8 0.8 6.6 5.5 1.1 6.6 5.7 0.9 
4ARG NH HA --- 6.2 8.0 1.8 6.2 6.7 0.5 6.2 7.4 1.2 
4ARG HA HB1 pro-R 9.0 8.7 0.3 9.0 11.1 2.1 9.0 9.8 0.8 
4ARG HA HB2 pro-S 5.6 5.2 0.4 5.6 3.8 1.8 5.6 4.5 1.1 
5GLY NH HA1 pro-R 5.0 5.4 0.4 5.0 4.2 0.8 5.0 4.9 0.1 
5GLY NH HA2 pro-S 6.9 5.1 1.8 6.9 7.2 0.3 6.9 6.1 0.8 
 
d) Remarks 
DPHG: D-phenylglycine, IASP: iso-aspartic acid 
The MD runs of 11 as zwitter ionic and uncharged peptide result in obvious violations of ROE 
based distance restraints and of scalar couplings. If both runs, each 250 ns long, are 
combined (the first frame of the "zwitter ionic run" is added to last frame of the "uncharged 
run") to one trajectory of 500 ns length, and pairwise proton distances and dihedral angle 
averages are evaluated again, all parameters are in very good agreement with the 
experimentally yielded NMR data. The table below shows the population of clustered peptide 
family members of 11 arising within the 500 ns trajectory (based on a backbone RMSD cut-off 
of 0.4 Å using the Gromos cluster[19] algorithm). Remaining violations show that the available 
conformational space of 11 was not completely sampled. For our computational docking runs, 
the two most representative conformations ("Structure 1 & 2") of 11 were used but only the 
uncharged species led to meaningful results as presented in the main text. Hence, only this 
conformation was discussed in the manuscript. 
Structure 1 Structure 2 Structure 3 Structures 4-26 
48 % (Zwitter) 32 % (Uncharged) 7 % 13 % 
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10. NMR & MD data for peptide 13: c(-DPhg-Gly-IAsp-Gly-Arg-) 
 
a) Assignment (given in ppm) 
1DPHG 2GLY 3IASP 4GLY 5ARG 
NH --- 8.61 NH --- 8.65 NH --- 7.77 NH --- 8.47 NH --- 8.02 
HA --- 5.27 HA1 pro-R 3.66 HA --- 4.48 HA1 pro-R 3.56 HA --- 4.32 
HD* --- 7.39 HA2 pro-S 3.78 HB1 pro-R 2.63 HA2 pro-S 3.79 HB1 pro-R 1.51 
HE* --- 7.35 HB2 pro-S 2.78  HB2 pro-S 1.73 
HZ --- 7.37 
 
 HG* --- 1.41 
HD* --- 3.09  
HE --- 7.57 
 
b) ROE distance restraints 
Assignment Experimental (Å) Zwitter (Å) Uncharged (Å) Combined (Å) 
No AS-1 At-1 AS-2 At-2 Upper Lower Calc Viol Calc Viol Calc Viol 
01 1DPHG HA 1DPHG NH 3.45 2.82 2.77 - 0.05 2.80 - 0.02 2.79 - 0.03 
02 1DPHG HA 2GLY NH 2.81 2.30 2.39  2.37  2.38  
03 2GLY NH 2GLY HA2 3.06 2.50 2.63  2.67  2.65  
04 2GLY NH 2GLY HA1 3.07 2.51 2.46 - 0.05 2.39 - 0.12 2.43 - 0.08 
05 3IASP NH 2GLY HA1 3.43 2.81 3.19  3.23  3.21  
06 2GLY NH 3IASP NH 3.24 2.65 3.65 + 0.42 3.05  3.30 + 0.07 
07 3IASP NH 3IASP HA 2.97 2.43 2.76  2.72  2.74  
08 4GLY NH 3IASP HA 4.06 3.32 3.59  3.64  3.62  
09 3IASP NH 3IASP HB1 4.38 3.58 3.51 - 0.07 3.34 - 0.24 3.42 - 0.16 
10 4GLY NH 3IASP HB1 3.20 2.62 2.84  3.42 + 0.22 3.08  
11 3IASP NH 3IASP HB2 3.86 3.16 2.49 - 0.67 3.81  2.89 - 0.27 
12 4GLY NH 3IASP HB2 2.90 2.38 2.33 - 0.05 2.52  2.41  
13 5ARG NH 4GLY HA2 3.54 2.90 3.07  3.16  3.11  
14 5ARG NH 4GLY HA1 3.15 2.58 2.25 - 0.33 2.46 - 0.12 2.35 - 0.23 
15 1DPHG NH 5ARG NH 3.80 3.11 3.98 + 0.17 3.52  3.72  
16 4GLY NH 5ARG NH 3.56 2.91 4.06 + 0.51 2.98  3.36  
17 1DPHG NH 5ARG HA 2.61 2.14 2.19  2.17  2.18  
18 5ARG NH 5ARG HA 3.38 2.76 2.74 - 0.02 2.46 - 0.30 2.58 - 0.18 
19 5ARG NH 5ARG HB2 3.16 2.59 2.41 - 0.18 2.65  2.52 - 0.07 
20 5ARG HA 5ARG HB2 2.95 2.41 2.70  2.74  2.72  
21 5ARG HE 5ARG HB2 3.64 2.98 3.55  3.66 + 0.02 3.61  
22 5ARG NH 5ARG HB1 3.81 3.12 3.07 - 0.05 3.33  3.19  
23 5ARG HA 5ARG HB1 3.09 2.53 2.57  2.52 - 0.01 2.55  
24 1DPHG NH 1DPHG HD* 4.23 2.72 2.66 - 0.06 2.78  2.72  
25 1DPHG HD* 2GLY NH 5.16 3.48 3.56  3.46 - 0.02 3.51  
26 5ARG HD* 5ARG HB2 3.62 2.22 2.87  2.99  2.93  
27 5ARG HD* 5ARG HB1 4.19 2.69 2.84  2.85  2.85  
 13
Assignment Experimental (Å) Zwitter (Å) Uncharged (Å) Combined (Å) 
28 5ARG HA 5ARG HD* 4.59 3.02 3.57  3.33  3.44  
29 5ARG HG* 5ARG NH 4.87 3.24 3.28  3.44  3.36  
30 5ARG HA 5ARG HG* 4.30 2.78 2.68 - 0.10 2.74 - 0.04 2.71 - 0.07 
31 5ARG HB1 5ARG HG* 3.88 2.44 2.47  2.47  2.47  
32 1DPHG NH 1DPHG HE* 5.36 3.65 4.89  5.09  4.99  
33 1DPHG HA 1DPHG HE* 4.81 3.20 4.70  4.69  4.69  
 
c) J-Couplings 
Assignment Zwitter (Hz) Uncharged (Hz) Combined (Hz) 
AS At-1 At-2 Chiral Exp Calc Viol Exp Calc Viol Exp Calc Viol 
1DPHG NH HA --- 7.3 8.6 1.3 7.3 7.7 0.4 7.3 8.1 0.8 
2GLY NH HA1 pro-R 6.4 6.7 0.3 6.4 5.7 0.7 6.4 6.2 0.2 
2GLY NH HA2 pro-S 5.9 5.5 0.4 5.9 5.9 0.0 5.9 5.7 0.2 
3IASP NH HA --- 8.2 7.0 1.2 8.2 8.2 0.0 8.2 7.6 0.6 
3IASP HA HB1 pro-R 3.5 3.6 0.1 3.5 2.8 0.7 3.5 3.2 0.3 
3IASP HA HB2 pro-S 7.5 3.5 4.0 7.5 11.2 3.7 7.5 7.4 0.1 
4GLY NH HA1 pro-R 5.4 5.7 0.3 5.4 4.7 0.7 5.4 5.2 0.2 
4GLY NH HA2 pro-S 6.5 6.4 0.1 6.5 7.0 0.5 6.5 6.7 0.2 
5ARG NH HA --- 7.3 7.3 0.0 7.3 6.7 0.6 7.3 7.0 0.3 
5ARG HA HB1 pro-R 8.5 9.8 1.3 8.5 8.7 0.2 8.5 9.2 0.7 
5ARG HA HB2 pro-S 5.4 4.7 0.7 5.4 5.5 0.1 5.4 5.1 0.3 
 
d) Remarks 
DPHG: D-phenylglycine, IASP: iso-aspartic acid 
The MD runs of 13 as zwitter ionic and uncharged peptide result in obvious violations of ROE 
based distance restraints and of scalar couplings. If both runs, each 250 ns long, are 
combined (the first frame of the "zwitter ionic run" is added to last frame of the "uncharged 
run") to one trajectory of 500 ns length, and pairwise proton distances and dihedral angle 
averages are evaluated again, all parameters are in excellent agreement with the 
experimentally yielded NMR data. The table below shows the population of clustered peptide 
family members of 13 arising within the 500 ns trajectory (based on a backbone RMSD cut-off 
of 0.4 Å using the Gromos cluster[19] algorithm). Remaining violations show that the available 
conformational space of 13 was not completely sampled. For our computational docking runs, 
only the most representative conformation ("Structure 1") of 13 was used, and only this 
conformation (uncharged) was discussed throughout our manuscript. 
Structure 1 Structure 2 Structure 3 Structures 4-20 
62 % (Uncharged) 18 % (Zwitter) 9 % 11 % 
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Conformational Details of Peptide 11 (as shown in the main text in Fig. 2) 
 
Residue Torsion Value Residue Torsion Value 
Phi 103° Phi -85° 
1DPHG 
Psi 36° 
4ARG 
Psi -47° 
Pseudo-Phi 164° Phi -176° 
Pseudo-Psi -66° 
5GLY 
Psi 97° 2IASP 
Iso-Bond 170° 
Phi 90° 
3GLY 
Psi -102° 
 
 
Distance 
2IASP-CA   -   4ARG-CA 
Distance 
2IASP-CG   -   4ARG-CB 
Plane Twist Angle 
2IASP-CG-CA   -   4ARG-CA-CB 
7.0 Å 9.4Å 161° 
 
 
 
Conformational Details of Peptide 13 (as shown in the main text in Fig. 2) 
 
Residue Torsion Value Residue Torsion Value 
Phi 86° Phi 83° 
1DPHG 
Psi -117° 
4GLY 
Psi -126° 
Phi -119° Phi -86° 
2GLY 
Psi 118° 
5ARG 
Psi 124° 
Pseudo-Phi 124° 
Pseudo-Psi -60° 3IASP 
Iso-Bond 149° 
 
 
Distance 
2IASP-CA   -   4ARG-CA 
Distance 
2IASP-CG   -   4ARG-CB 
Plane Twist Angle 
2IASP-CG-CA   -   4ARG-CA-CB 
7.1 Å 9.9 Å 164° 
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11. Molecular docking 
 
Methods 
Docking simulations 
Molecular docking of 11 and 13 in the X-ray three-dimensional structure of 
αvβ3 (PDB code: 1L5G) and in the α5β1 homology model published before, 
was carried out using the AutoDock 4.0 software package as implemented 
through the graphical user interface AutoDockTools (ADT 1.5.2).[20] 
 
Ligands and protein setup 
The conformations of peptides 11 and 13 as experimentally determined by 
NMR, distance geometry, and subsequent molecular dynamics (restrained 
MD) were used as docking starting structures (after energy minimization in 
vacuum). During the docking process the backbone conformation was held 
fix, while the side chain dihedral angles were free to rotate. Partial atomic 
charges were assigned by using the Gasteiger-Marsili formalism. 
 
Docking setup 
The docking area has been defined by a box, centered on the coordinate of 
the metal in the MIDAS region. Grid points of 70×70×70 with 0.375 Å spacing 
were calculated around the docking area for all the ligand atom types using 
AutoGrid4. For each ligand, 100 separate docking calculations were per-
formed. Each docking calculation consisted of 10 million energy evaluations 
using the Lamarckian genetic algorithm local search (GALS) method. A low-
frequency local search according to the method of Solis and Wets was 
applied to docking trials to ensure that the final solution represents a local 
minimum. Each docking run was performed with a population size of 150, and 
300 rounds of Solis and Wets local search were applied with a probability of 
0.06. A mutation rate of 0.02 and a crossover rate of 0.8 were used to 
generate new docking trials for subsequent generations. The GALS method 
evaluates a population of possible docking solutions and propagates the most 
successful individuals from each generation into the next one. The docking 
results from each of the 100 calculations were clustered on the basis of root-
mean square deviation (rmsd = 1.5 Å) between the Cartesian coordinates of 
the ligand atoms and were ranked on the basis of the free energy of binding. 
However, for each ligand, the free energy of binding as well as the con-
sonance with experimental data, such as receptor-mutagenesis and ligands 
SARs, were taken into account for the choice of the published binding modes. 
 
Further details on the docking of 11 into the αvβ3, implication for ligand 
selectivity and comparison with Cilengitide 
 
Predictably, the described favorable binding pose of 11 in αvβ3 cannot be 
found in the same receptor due to the fact that the pocket below the SDL is 
remarkably narrower in αvβ3 with respect to α5β1 due to the substitution of 
(β1)-Leu219, (β1)-Ser171, (β1)-Gly217 with (β3)-Arg216 (β3)-Tyr166 (β3)-
Arg214 respectively. Indeed, in the search of α5β1- selective ligands we were 
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previously successful in targeting this region.[21] Moreover, docking 
calculations of 11 into the avb3 receptor suggest a certain difficulty for the Arg 
guanidinium group to insert into the narrow groove at the top of the propeller 
domain, where salt bridge to Asp218 and/or Asp150 should occur. In fact over 
100 proposed conformation, only10 display one of the two salt bridges (one of 
the ten is shown in Figure SI_2 superimposed to the experimental binding 
mode of Cilengitide). Probably, this is due to the peculiar conformation of the 
peptidic cycle together with the forced position of the phenyl ring which cannot 
occupy the wide pocket below the SDL peculiar of the α5β1 receptor. This 
evidence together with the unfavourable position of the phg phenyl ring seems 
to be the reason for a low binding to the αvβ3 receptor.  
 
 
Figure SI_2: Superposition of a theoretical binding mode of 11 (white) and 
the experimental (X-ray) binding mode of Cilengetide (green) 
in αvβ3.  
Further details on docking calculations of 13 in a5b1, implication for 
ligand selectivity and comparison with Cilengitide 
Docking studies of 13 in α5β1 receptor resulted in an ambiguous position of 
the phg aromatic ring within the RGD binding pocket. Indeed, two main poses 
were found, which have in common the interactions with metal in the MIDAS 
and with D227 side chain and which primarily differ for the orientation of the 
phg aromatic ring (see Figure SI_3). Interestingly, the two binding modes 
show similar free energy of binding and this is in perfect line with the 
observation that in both orientation the phg aromatic ring of 13 does not 
engage any strong interaction with the receptor residues as found when 
docking of 13 was performed in αvβ3. Thus, it seems that the favourable 
interactions between the phg aromatic ring of 13 and the (αv)-Tyr178, (β3)-
Tyr166, (β3)-Arg214 residues, which are characteristic for αvβ3, are the 
reason for an higher binding to the αvβ3 receptor. 
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Figure SI_3: The two main binding poses of 13 (yellow and green) in the 
α5β1 integrin binding pocket.  
 
 
Figure SI_4: Superposition of theoretical binding mode of 13 (yellow) and 
experimental (X-ray) binding mode of Cilengetide (green) in 
αvb3. Although the aromatic ring in 13 and Cilengitide are 
differently oriented, both are able to establish favorable 
contacts with the receptor residues (see main text of the 
manuscript for the description of interactions). 
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Figure SI_5: Docked structure (alternative pose) of 13 (pale yellow) in the 
αvβ3 integrin binding pocket. The αv and β3 subunits are 
represented by the blue and cyan surface respectively. In both 
subunits amino acid side chains important for the ligand 
binding are highlighted as sticks. The metal ion in the MIDAS 
region is represented by a purple sphere. 
 
Ability of Cilengetide to fit the a5b1 binding pocket 
The ability of Cilengitide to bind the RGD binding site of the a5b1 homology 
model was tested in 2005 for a previous work focused on the a5b1 receptor 
(J. Med. Chem. 2005, 48, 4166 – 4204.). It was found that Cilengitide binds 
the a5b1 in the same manner as found experimentally for avb3. However, the 
attachment of the Arg guanidinium moiety of the Cilengitide to the a5b1 
propeller domain is expected to be less strong with respect to that to αvβ3 
due to the substitution of αv-D150 with α5-A159. 
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12. Cell assays 
 
 
 
 
Figure SI_6: a) Blocking assay of Cilengitide (green), 11 (rot) and 13 (black) 
with αvβ3 expressing cells.  b) Assay with α5β1 expressing 
cells; 1 = 10 nM, 2 = 100 nM, 3 = 1000 nM, 4 = 10000 nM, 5 = 
100000 nM 
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Cells 
Mouse fibroblast cell lines expressing either αvβ3 or α5β1 were generated 
from fibroblasts derived from the kidney of αvflox/flox, β1flox/flox, β2-/- , β7-/- mice 
(manuscript in preparation). Cells were immortalized by retroviral transduction 
of the SV40 large T and cloned. Subsequently the cells were retrovirally 
transduced with mouse αv or β1 integrin expression constructs. Endogenous 
β1 and αv integrin loci were deleted by adenoviral cre-recombinase 
transduction. Selective expression of αvβ3 or α5β1 was verified by flow 
cytometry and immunoblotting. 
 
Adhesion blocking assay 
To evaluate cell adhesion 96 well plates were coated for 2 h at room 
temperature with 5µg/mL fibronectin in PBS and then blocked with 1% bovine 
serum albumin. Fibroblasts expressing αvβ3 or α5β1 were incubated with 
increasing concentrations (10 - 100000 nM) of the cyclic peptides for 20 min. 
on ice. Then 40000 cells/well were seeded onto the fibronectin coated plates 
in presence of the cyclic peptides and incubated for 40 minutes at 37°C. After 
washing off non-adherent cells the adherent cells were fixed, stained with 
crystal violet and the relative percentage of adherent cells was determined as 
previously described.[22] The percentage of adherent cells treated with 
increasing cyclic peptide concentrations relative to untreated cells was 
calculated from 3 independent experiments (n=16; means and standard error 
of the means are shown). To calculate IC50 values dose response curves 
were fitted onto the data using the SigmaPlot software. 
 
Relative binding activities 
Comparing the ratios of the respective IC50 values shows that in fact the 
selectivity of peptide 11 is the same for the two independent experimental 
systems. The selectivity of peptide 13 however was slightly better in the 
competitive solid phase ELISA. Overall, there is a good correlation between 
the two observations. 
 
IC50 ratios α5β1 cell line αvβ3 cell line 
Cellular adhesion 
blocking assay:   
Ratio IC50  11/13 0.05 2.8 
Ratio IC50  Cil/11 0.47  0.009 
Ratio IC50  Cil/13  0.09  0.02 
   
Competitive solid 
phase ELISA:   
Ratio IC50 11/13 0.05 11.23 
Ratio IC50 cil/11 0.78  0.00054 
Ratio IC50 cil/13 0.04  0.006 
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